Moderna (MRNA) expects 1.9 billion in 2025 sales while trimming its cost forecast, signaling improved operational efficiency amid COVID vaccine demand challenges.
The updated revenue projection sits near the upper end of the biotech company’s previously announced range of 1.5 billion to 2.5 billion, suggesting better-than-expected performance despite ongoing headwinds in the vaccine market.
Key Takeaways
- Revenue forecast of 1.9 billion exceeds previous midpoint expectations
- Cost reduction initiatives targeting 1 billion in cash savings
- Most 2025 revenue expected in second half of year
Market reaction & context
The revenue guidance represents a significant recovery from earlier concerns about slumping COVID vaccine demand. Moderna’s updated forecast of 1.9 billion is 100 million higher than the midpoint it previously projected 2.
The company had previously cut its 2025 revenue forecast by 1 billion in January, citing weak COVID vaccine sales and delayed product launches. Biotech peers have similarly struggled with post-pandemic demand normalization.
Detailed analysis
Moderna’s cost-cutting efforts aim to reduce 2025 cash costs by 1 billion as the company transitions from pandemic-era operations to a more sustainable business model 8. The majority of projected revenue will materialize in the second half of 2025, primarily driven by Spikevax sales.
The company is expanding its cost reduction initiatives beyond initial plans, reflecting management’s focus on operational efficiency. These measures come as Moderna faces ongoing challenges from reduced government COVID vaccine purchases and increased market competition.
Outlook & management perspective
Chief Executive Stéphane Bancel outlined the revenue projections in a recent shareholder letter, emphasizing the company’s product launch strategy for 2025 5. The guidance reflects Moderna’s efforts to diversify beyond COVID vaccines while maintaining profitability.
Analysts had expected average revenue of 2.92 billion for 2025 according to FactSet, making Moderna’s projection more conservative than Street expectations 9. The company’s ability to meet its 1.9 billion target will depend heavily on seasonal vaccine demand patterns and successful product launches.
Conclusion
Moderna’s updated 2025 forecast suggests stabilizing business fundamentals despite industry-wide vaccine demand challenges. The combination of improved revenue visibility and aggressive cost management positions the company for a potential recovery.
Investors will closely monitor execution on both revenue targets and cost reduction initiatives as Moderna navigates the transition from pandemic response to sustainable growth. The second-half revenue weighting creates execution risk but aligns with typical seasonal vaccine patterns.
Not investment advice. For informational purposes only.
References
1(January 12, 2026). “Moderna expects 1.9 billion in sales, trims costs forecast for 2025”. Reuters. Retrieved January 12, 2026.
2(January 12, 2026). “Moderna Expects 2025 Revenue of 1.9 Billion”. MarketScreener. Retrieved January 12, 2026.
3(November 6, 2025). “Moderna trims annual expenses outlook on lower production costs”. Yahoo Finance. Retrieved January 12, 2026.
4(January 14, 2025). “Moderna Cuts 2025 Revenue Forecast by 1 Billion, Shares Drop”. MSN. Retrieved January 12, 2026.
5(January 5, 2026). “Moderna targets 1.6-2.0 billion revenue for 2025 amid product launches”. StreetInsider. Retrieved January 12, 2026.
6(January 13, 2025). “Moderna lowers 2025 sales forecast by 1 billion”. CNBC. Retrieved January 12, 2026.
7(August 1, 2025). “Moderna Cuts Sales Forecast on UK Revenue Delay, Shares Fall”. US News. Retrieved January 12, 2026.
8(January 13, 2025). “Moderna Aims To Reduce 2025 Cash Costs By 1 Billion”. Nasdaq. Retrieved January 12, 2026.
9(January 13, 2025). “Moderna surprises the Street by predicting a bigger-than-expected sales drop”. KTSM. Retrieved January 12, 2026.